ArticleThe Journal of infectious diseases2025
Therapeutic Inhibition of Metalloproteases by Tetracyclines During Infection by Multidrug-Resistant Pseudomonas.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Evolving Microbial Paradigm in Acne.Biomolecules · 2026Review
- Pentamidine inhibition of streptopain attenuatesMicrobiology spectrum · 2025Article
- Pentamidine inhibition of streptopain attenuatesbioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The secreted bacterial metalloprotease LasB contributes to inflammation and tissue damage during Pseudomonas aeruginosa pulmonary infections. We investigate whether tetracyclines inhibit LasB by computational modeling and biochemical assays, then examined their efficacy in model infections with human neutrophils in vitro and in a murine pulmonary model. Tetracycline, doxycycline, minocycline, and tigecycline all inhibited LasB proteolysis, while other relevant antibiotics did not. At subantimicrobial concentrations, tetracyclines sensitized Pseudomonas to neutrophil killing and significantly reduced lung pathology, even for multidrug-resistant strains. By controlling pathological host responses, inhibiting bacterial virulence factors, and facilitating bacterial killing, tetracyclines can thus have tripartite therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.